Marksans Pharma Limited has informed the Exchange regarding a press release dated May 19, 2025, titled "Press Release dated 19 May 2025 regarding audited financial results for the quarter and year ended 31 March 2025".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.9 pts less than Nifty Microcap 250 and 5.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma reported record-high annual revenue and profits for FY25. Operating revenue grew 20.5% YoY to Rs. 2,622.8 cr, while PAT rose 21.5% to Rs. 382.6 cr, with EPS at Rs. 8.4. The US business was the key growth driver, expanding 34.7% YoY to Rs. 1,236.6 cr, while UK & Europe grew 9.2% and Australia/NZ rose 15.5%. For Q4FY25, revenue jumped 26.5% YoY to Rs. 708.5 cr and EBITDA grew 14.7% to Rs. 125.8 cr. Gross margin expanded sharply by 407 bps YoY to 56.4% for the full year, helped by lower raw material costs and a better product mix. The company also commercialized 58 products in the US and has 79 products in its US pipeline.
A clean beat across revenue, profits, and margins — led by strong US growth and expanding gross margins — is positive for the stock. Robust cash balance of Rs. 704.2 cr and ongoing capex on the Goa facility support the growth outlook.